Please assess the completion status of the following clinical trial:

Trial Title: Thoracic Endoprosthesis for Treatment of Aneurysm of the Descending Thoracic Aortic

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:\>~1. Presence of DTA aneurysm deemed to warrant surgical repair \>~* Fusiform (≥50 mm), or \>~* Saccular (no diameter criteria)\> 2. Subject is \> 21 years of age\> 3. Proximal and distal landing zone length ≥ 2.0 cm \>~* Landing zones must be in native aorta\>~* Landing zone may include left subclavian artery, if necessary\> 4. All proximal and distal landing zone inner diameters are between 16-42 mm\>~* Diameter assessed by flow lumen and thrombus, if present; calcium excluded\> 5. Life expectancy \> 2 years\> 6. Able to tolerate thoracotomy \> 7. Male or infertile female\> 8. Able to comply with protocol requirements including following-up\> 9. Signed informed consent\>~Exclusion Criteria:\>~1. Differing proximal and distal neck diameters (aortic taper) outside the intended aortic diameter requirements (sizing guide) for a single endoprosthesis diameter and the inability to use devices of different diameters (in adherence to the sizing guide) to compensate for the taper\>~2. Tortuous or stenotic iliac and/or femoral arteries and inability to use a conduit for vascular access\>~3. Aneurysmal, dissected, heavily calcified, or heavily thrombosed landing zone(s)\>~4. Mycotic aneurysm\>~5. Hemodynamically unstable aneurysm rupture\>~6. Aortic dissection\>~7. Planned coverage of left carotid or celiac arteries with the CTAG Device\>~8. Planned concomitant surgical procedure (other than left subclavian transposition and wireless sac pressure monitoring), or major surgery within 30 days of treatment date\>~9. Known degenerative connective tissue disease, e.g. Marfan or Ehler-Danlos Syndrome\>~10. Known history of drug abuse\>~11. ASA risk classification = V (moribund patient not expected to live 24 hours with or without operation)\>~12. NYHA class IV \>~13. Participating in another investigational device or drug study within 1 year of treatment\>~14. Subject has known sensitivities or allergies to the device materials\>~15. Subject has a systemic infection and may be at increased risk of endovascular graft infection\>

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GORE CTAG Device (Type: EXPERIMENTAL): The primary endpoint of this study is freedom from a Major Device Event (MDE) through 1 month post-treatment in subjects treated with the GORE® Conformable TAG® Thoracic Endoprosthesis.

Based on this trial design, predict the completion outcome and termination type (if applicable).